Neurology News and Research

Latest Neurology News and Research

FDA confirms Advisory Committee meeting date for lorcaserin NDA review

Arena Pharmaceuticals, Inc. and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has notified the company of the confirmed scheduling of an Endocrinologic and Metabolic Drugs Advisory Committee meeting on September 16, 2010, for the review of the lorcaserin New Drug Application (NDA). Lorcaserin, which Arena discovered and has developed for weight management, is intended for obese patients as well as overweight patients who have at least one weight-related co-morbid condition.

7 Aug 2010

Drugs that reduce activity of ABDH6 enzyme can prevent brain damage: Study

A newly discovered molecular mechanism helps control the amount and effectiveness of a substance that mimics an active ingredient in marijuana, but that is produced by the body's own nerve cells.

7 Aug 2010

AVANIR Pharmaceuticals reports net loss of $5.7M for third-quarter fiscal 2010

AVANIR Pharmaceuticals, Inc. today reported unaudited financial results for the three and nine months ended June 30, 2010.

7 Aug 2010

TEMPO study recommends early administration of Azilect in PD patients

Teva Pharmaceutical Industries Ltd. and H. Lundbeck A/S (Lundbeck) today announced newly published long-term data on Azilect(rasagiline tablets) from the TEMPO study and its open-label extension. The findings confirm the long-term efficacy, safety and tolerability of Azilect® in patients with Parkinson's disease (PD) and further demonstrate the benefits obtained with early treatment initiation. The data was published in the June 2010 issue of the International Journal of Neuroscience.

6 Aug 2010

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen Corporation today reported results for the first quarter of fiscal year 2011, ended June 30, 2010. Total revenue for the first quarter was $7,010,000 compared to total revenue of $5,061,000 for the first quarter of fiscal year 2010, an increase of $1,949,000 or 39%. Bioprocessing product revenue for the first quarter was $4,269,000 compared to $2,473,000 for the first quarter of fiscal 2010, an increase of $1,796,000 or 73%.

5 Aug 2010

New studies question wide-spread hypothesis that CCSVI contribute to development of MS

Researchers at Umeå University in Sweden have performed a study that indicates that neither blood flow nor the flow of spinal fluid in the brain contribute to the development of multiple sclerosis, MS. The findings run directly counter to a much-discussed and widely spread Italian theory.

5 Aug 2010

Scientists discover Deep Brain Stimulation as potential treatment for early Alzheimer's

In a world first, Dr. Andres M. Lozano and his team at Toronto Western Hospital has shown using Deep Brain Stimulation (DBS) on patients with early signs of Alzheimer's disease is safe and may help improve memory. The phase one safety trial of six Ontario patients took place from 2005 to 2008. All patients left hospital within 2 to 3 days of surgery, and continue to participate in regular follow-up cognitive assessments.

5 Aug 2010

Detection of Alzheimer's before symptoms occur

Research is on to detect the dreaded Alzheimer's disease even before any symptoms occur. In a newly proposed diagnostic criteria developed by experts from the National Institute on Aging and the Alzheimer's Association three stages of the disease viz. pre-clinical Alzheimer's, mild cognitive impairment and Alzheimer's dementia are described.

4 Aug 2010

Special issue on new developments in vestibular rehabilitation

Rehabilitation is essential for patients with disabling symptoms of dizziness, vertigo, and unsteadiness caused by disorders of the vestibular system. A special issue of The Journal of Neurologic Physical Therapy (JNPT) presents an update on new and emerging vestibular rehabilitation techniques, highlighting the physical therapist's role on the multidisciplinary teams providing patient care and research.

4 Aug 2010

MAP Pharmaceuticals reports net loss of $12.5M for second-quarter 2010

MAP Pharmaceuticals, Inc. today announced financial results for the second quarter ended June 30, 2010.

3 Aug 2010

Other brain regions compensates loss of amygdale: Research

Many neuroscientists believe the loss of the brain region known as the amygdala would result in the brain's inability to form new memories with emotional content. New UCLA research indicates this is not so and suggests that when one brain region is damaged, other regions can compensate.

3 Aug 2010

Healthy heart may slow down aging of brain: Study

Keep your heart healthy and you may slow down the aging of your brain, according to a new study reported in Circulation: Journal of the American Heart Association.In the study, people whose hearts pumped less blood had brains that appeared older than the brains of those whose hearts pumped more blood. Decreased cardiac index, the amount of blood that pumps from the heart in relation to a person's body size, was associated with decreased brain volume using magnetic resonance imaging (MRI).

3 Aug 2010

GG genotype may increase severity of multiple sclerosis symptoms: Study

A new study shows a gene variant may increase the severity of multiple sclerosis (MS) symptoms. The research will be published in the August 3, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.For the study, researchers screened the oligoadenylate synthetase gene in 401 people with MS, 394 people without MS and 178 people receiving the MS treatment beta interferon.

3 Aug 2010

Repligen receives three additional grants to develop HDAC inhibitors for neurodegenerative diseases

Repligen Corporation today announced that the Company has received three additional grants to support its research program to develop HDAC inhibitors for neurodegenerative diseases. Repligen has received $436,000 in research funding to support the ongoing development of histone deacetylase inhibitors for Friedreich's ataxia.

2 Aug 2010

Xeomin receives FDA approval for treatment of cervical dystonia

Merz Pharmaceuticals today announced that the United States Food and Drug Administration has approved Xeomin (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm. According to an epidemiology study conducted in Rochester, Minnesota, the prevalence of focal dystonia, which includes cervical dystonia and blepharospasm, is estimated at 295 per million people in the U.S.

2 Aug 2010

Verizon Business to help courts, prison health care systems with new technology solutions

Courts grappling with jammed dockets and prisons struggling to handle inmate health care issues can now put the power of video collaboration to work, with a new, tailored set of technology solutions and professional consulting services from Verizon Business.

2 Aug 2010

Research shows no link between CCSVI and development of multiple sclerosis

Two important new studies challenge the controversial hypothesis that venous congestion—chronic cerebrospinal venous insufficiency (CCSVI)—contributes to the development of multiple sclerosis (MS). This theory has resulted in many MS patients receiving experimental endovascular angioplasty, a treatment for MS unproven by clinical trials.

2 Aug 2010

Oral contraceptives, HRT may protect women against formation, rupture of brain aneurysms: Study

Results from a new study suggest that oral contraceptives and hormone replacement therapy may yield additional benefit of protecting against the formation and rupture of brain aneurysms in women. The findings from this first-of-its-kind study by a neurointerventional expert from Rush University Medical Center were presented at the Society of Neurointerventional Surgery 7th annual meeting.

31 Jul 2010

Measuring GAPDH inhibiting antibodies can result in long-term treatment for MS

UCI immunologists have found that testing for increased levels of antibodies that inhibit energy production in neurons can detect axon and neuron degeneration in multiple sclerosis earlier than existing diagnostic tools.

31 Jul 2010

Study shows estrogen stabilization may protect women from brain aneurysms risk

Results from a retrospective, case-control study presented today at the Society of NeuroInterventional Surgery (SNIS) 7th Annual Meeting could have significant implications for women at risk of brain aneurysms as data shows that oral contraceptives (OC) and hormone replacement therapy (HRT) may yield the additional benefit of protecting against the formation and/or rupture of brain aneurysms – balloon-like sacks that form in a weakened artery wall and, upon bursting, can cause severe disability or death.

31 Jul 2010